secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-10-10T23:59:59+00:00
Accession:  0001356576-24-000056
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus to review Phase 2a data for SPN-820 in major depressive disorder on Oct 17
--------------------------------------------------------------------------------

- Company will host webcast and conference call on October 17, 2024 at 4:30 PM ET.
- Event will review data from open-label Phase 2a study of SPN-820 for major depressive disorder.
- No specific results are disclosed in this filing; data will be presented during the webcast.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000056/0001356576-24-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000056/supn-20241010.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer